Correlation Engine 2.0
Clear Search sequence regions

  • cell movement (1)
  • DLEU2 (10)
  • E2F2 (5)
  • e2f2 protein (1)
  • factor (2)
  • gene (1)
  • humans (3)
  • kinases (2)
  • micrornas (3)
  • MIRN582 (1)
  • patients (1)
  • poor prognosis (1)
  • prostate (10)
  • protein human (1)
  • rnas (7)
  • serum protein (1)
  • SGK1 (3)
  • Sizes of these terms reflect their relevance to your search.

    Long noncoding RNAs (lncRNAs) participate in biological processes in multiple types of tumors. However, the regulatory patterns of lncRNAs in prostate cancer remain largely unclear. Here, we evaluated the expression and roles of the lncRNA DLEU2 in prostate cancer. Our results showed that DLEU2 was upregulated in advanced prostate cancer tissues. Patients with prostate cancer displaying high expression of DLEU2 had a poor prognosis. Moreover, we demonstrated that overexpression of DLEU2 facilitated the proliferation, migration, and invasion of prostate cancer in vitro. Mechanistically, DLEU2 promoted serum and glucocorticoid-induced protein kinase 1 (SGK1) expression by acting as an miR-582-5p sponge, and the transcription of DLEU2 was activated by the dysregulation of E2F transcription factor 2 (E2F2) expression in prostate cancer. Furthermore, knockdown of DLEU2 attenuated prostate cancer tumorigenesis in vivo. Notably, these findings suggested that E2F2-activated DLEU2 may function as a competing endogenous RNA to facilitate prostate cancer progression by targeting the miR-582-5p/SGK1 axis. © 2022. The Author(s).


    Peizhang Li, Huan Xu, Liu Yang, Ming Zhan, Yuanping Shi, Caoxu Zhang, Dajun Gao, Meng Gu, Yanbo Chen, Zhong Wang. E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1. Cell death & disease. 2022 Jan 24;13(1):77

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35075115

    View Full Text